Richtlijn 'Behandeling van het mammacarcinoom 2008' (herziening)

H. Struikmans, J. W. R. Nortier, E. J. T. Rutgers, H. M. Zonderland, M. Bontenbal, P. H. M. Elkhuizen, G. van Tienhoven, V. C. G. Tjan-Heijnen, T. van Vegchel, M. K. Tuut, J. Benraadt

Research output: Contribution to journalArticleProfessional


- The Dutch evidence-based guideline 'Treatment of breast cancer' has been revised, and integrated with the guideline 'Screening for and diagnosis of breast cancer'. The guideline can be found on www. and on - The Internet programme 'Adjuvant!' ( can be used to predict both the prognosis and the efficacy of systemic adjuvant therapy for each patient. - The indications for adjuvant chemotherapy and endocrine therapy have been widened. The aim is to reduce the absolute probability of death by at least 4-5% within 10 years. - The goal of neoadjuvant chemotherapy in operable breast cancer is to enable breast-conserving therapy for large tumours in relatively small breasts. - One could consider transferring responsibility for follow-up after 5 years from the hospital to the screening organisation following mastectomy, to the family doctor following breast-conserving therapy, and to an outpatient clinic for hereditary tumours in carriers of gene mutation. Cessation of follow-up above the age of 75 could also be considered.
Original languageDutch
Pages (from-to)2507-2511
JournalNederlands Tijdschrift voor Geneeskunde
Issue number46
Publication statusPublished - 2008
Externally publishedYes

Cite this